Education
About Us
Working with TipRanks
Follow Us
Shl Telemedicine Ltd. ADR (SHLT)
NASDAQ:SHLT
Top Page
Shl Telemedicine Ltd. ADR
(NASDAQ:SHLT)
48Neutral
Shl Telemedicine Ltd. ADR (SHLT) vs. S&P 500 (SPY)
Market Cap
$43.44M
Dividend YieldN/A
Average Volume (3M)3.59K
Price to Earnings (P/E)―
Beta (1Y)0.57
Revenue Growth-0.88%
EPS Growth-272.10%
CountryUS
Employees583
SectorHealthcare
Sector Strength78
IndustryHealthcare Providers & Services
Share Statistics
EPS (TTM)-0.54
Shares Outstanding16,392,754
10 Day Avg. Volume4,377
30 Day Avg. Volume3,591
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.66
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Shl Telemedicine Ltd. ADR Business Overview & Revenue Model
Company DescriptionSHL Telemedicine Ltd. ADR (SHLT) is a company that operates in the telemedicine sector, providing remote healthcare services and solutions. The company specializes in developing and offering advanced personal telemedicine systems and services, which enable individuals to manage their health and receive medical support from healthcare professionals remotely. SHL's core offerings include cardiac monitoring devices, telemedicine platforms, and related healthcare services designed to enhance patient outcomes and streamline healthcare delivery.
How the Company Makes MoneySHL Telemedicine Ltd. generates revenue through the sale and deployment of its telemedicine solutions and services. Key revenue streams include the sales of cardiac monitoring devices, subscription fees for access to its telemedicine platforms, and service fees for remote healthcare monitoring and consultation services. The company often partners with healthcare providers, insurance companies, and other entities to integrate its solutions into broader healthcare offerings, thereby expanding its market reach and customer base. Additionally, SHL may derive income from licensing agreements and collaborations with other companies in the healthcare technology sector.
Shl Telemedicine Ltd. ADR Financial Statement Overview
Summary
The company's financial performance is challenged by declining revenues and profitability issues. The income statement shows a negative revenue growth rate and operating losses. The balance sheet indicates a stable capital structure with manageable leverage, but ongoing losses impact return on equity. Cash flow analysis reveals liquidity challenges with negative free cash flow and difficulty converting income into cash.Income Statement
The income statement shows declining revenue with a negative revenue growth rate from 2022 to 2023. Gross profit margin has decreased to 44.26% in 2023 from 46.07% in 2022. The company is also operating at a loss with a negative EBIT and net income, indicating challenges in profitability and operational efficiency.45
Neutral
Balance Sheet
The balance sheet reveals a moderate debt-to-equity ratio of 0.27 in 2023, indicating manageable leverage. However, the return on equity is negative, reflecting the ongoing losses. The equity ratio is solid at 65.03%, suggesting a strong capital structure with significant equity backing.60
Neutral
Cash Flow
Cash flow analysis shows negative free cash flow, indicating liquidity challenges. The operating cash flow to net income ratio is negative, highlighting difficulties in converting income to cash. The free cash flow to net income ratio is also negative, suggesting ongoing cash flow constraints.50
Neutral
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 55.94M | 57.08M | 59.00M | 49.58M | 40.16M | 41.88M | Gross Profit |
| 25.58M | 25.26M | 27.19M | 24.59M | 20.64M | 23.46M | EBIT |
| -7.86M | -9.01M | -5.17M | -497.00K | 396.00K | 4.77M | EBITDA |
| -1.96M | 3.28M | 2.14M | -7.25M | 5.41M | 9.22M | Net Income Common Stockholders |
| -8.84M | -7.06M | -76.00K | -14.11M | 278.00K | 5.70M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 6.08M | 26.25M | 18.70M | 32.06M | 10.62M | 6.08M | Total Assets |
| 59.80M | 113.05M | 110.78M | 129.59M | 64.81M | 59.80M | Total Debt |
| 12.28M | 19.86M | 26.74M | 32.50M | 14.57M | 12.28M | Net Debt |
| 6.20M | 13.17M | 22.26M | 17.66M | 10.43M | 6.20M | Total Liabilities |
| 25.06M | 36.59M | 51.49M | 68.83M | 26.94M | 25.06M | Stockholders Equity |
| 34.74M | 73.53M | 55.69M | 56.85M | 37.88M | 34.74M |
| Cash Flow | Free Cash Flow | ||||
| -127.00K | -6.97M | -6.98M | -3.07M | 2.91M | 8.88M | Operating Cash Flow |
| 1.45M | -1.50M | -73.00K | 185.00K | 4.68M | 10.85M | Investing Cash Flow |
| 8.23M | -9.35M | -6.43M | -40.97M | -7.65M | 2.47M | Financing Cash Flow |
| -5.27M | 13.67M | -2.28M | 51.08M | 723.00K | -11.89M |
Shl Telemedicine Ltd. ADR Technical Analysis
Neutral
2.60
Price Trends
2.62
Negative
2.74
Negative
3.51
Negative
Market Momentum
-0.05
Negative
54.42
Neutral
69.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SHLT, the sentiment is Neutral. The current price of 2.6 is above the 20-day moving average (MA) of 2.35, below the 50-day MA of 2.62, and below the 200-day MA of 3.51, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 54.42 is Neutral, neither overbought nor oversold. The STOCH value of 69.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SHLT.
Shl Telemedicine Ltd. ADR Risk Analysis
Shl Telemedicine Ltd. ADR disclosed 45 risk factors in its most recent earnings report. Shl Telemedicine Ltd. ADR reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Shl Telemedicine Ltd. ADR Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $11.58B | 61.60 | 21.24% | ― | 17.47% | 49.87% | |
64 Neutral | $1.23B | ― | -12.28% | ― | 0.92% | -64.63% | |
49 Neutral | $6.90B | -0.08 | -53.01% | 2.43% | 24.84% | -3.06% | |
48 Neutral | $43.44M | ― | -12.35% | ― | -0.88% | -272.10% | |
46 Neutral | $1.72B | ― | -14.75% | ― | -32.45% | 80.24% | |
45 Neutral | $1.56B | ― | -52.46% | ― | -1.26% | -338.56% | |
43 Neutral | $127.07M | ― | -54.13% | ― | -1.81% | 70.88% |
* Healthcare Sector Average
Performance Comparison
SHLT
Shl Telemedicine Ltd. ADR
2.60
-3.65
-58.40%
MD
Pediatrix Medical Group
14.04
4.65
49.52%
TDOC
Teladoc
9.00
-6.14
-40.55%
AMWL
American Well
8.14
-10.73
-56.86%
CLOV
Clover Health Investments
3.36
2.56
320.00%
DOCS
Doximity
64.30
36.40
130.47%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.